⇚ Regimen IDHIFA® - for Acute Myeloid Leukemia Medical Name IDHIFA® (Enasidenib) for Acute Myeloid Leukemia (AML) with IDH2 mutation Cycles Given N/A Delivery Phases N/A Special Instructions Select patients for the treatment of AML with IDHIFA® based on the presence of IDH2 mutations in the blood or bone marrow. Monitor patients closely for symptoms of differentiation syndrome, leukocytosis, elevated bilirubin and GI toxicities. Monitor at a minimum of every 2 weeks for at least the first 3 months during treatment. Treatment continued until disease progression or unacceptable toxicity. In the absence of disease progression or unacceptable toxicity, treatment for a minimum of 6 months is recommended to allow time for a clinical response. References Stein EM, JCO 2017 - VIEW External References http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.7004 - VIEW Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration IDHIFA® (Enasidenib) PO 100 mg Daily N/A N/A N/A N/A